Eli Lilly and Co (LLY)
734.97
-20.94
(-2.77%)
USD |
NYSE |
May 03, 16:00
738.49
+3.52
(+0.48%)
After-Hours: 20:00
Eli Lilly Max Drawdown (5Y): 22.48% for April 30, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
April 30, 2024 | 22.48% |
March 31, 2024 | 22.48% |
February 29, 2024 | 22.48% |
January 31, 2024 | 22.48% |
December 31, 2023 | 22.48% |
November 30, 2023 | 22.48% |
October 31, 2023 | 22.48% |
September 30, 2023 | 22.48% |
August 31, 2023 | 22.48% |
July 31, 2023 | 22.48% |
June 30, 2023 | 22.48% |
May 31, 2023 | 22.48% |
April 30, 2023 | 22.48% |
March 31, 2023 | 22.48% |
February 28, 2023 | 22.48% |
January 31, 2023 | 22.48% |
December 31, 2022 | 22.48% |
November 30, 2022 | 22.48% |
October 31, 2022 | 22.48% |
September 30, 2022 | 22.48% |
August 31, 2022 | 22.48% |
July 31, 2022 | 22.48% |
June 30, 2022 | 22.48% |
May 31, 2022 | 22.48% |
April 30, 2022 | 22.48% |
Date | Value |
---|---|
March 31, 2022 | 22.48% |
February 28, 2022 | 22.48% |
January 31, 2022 | 22.48% |
December 31, 2021 | 22.48% |
November 30, 2021 | 22.48% |
October 31, 2021 | 22.48% |
September 30, 2021 | 22.85% |
August 31, 2021 | 24.25% |
July 31, 2021 | 24.25% |
June 30, 2021 | 24.25% |
May 31, 2021 | 24.25% |
April 30, 2021 | 24.25% |
March 31, 2021 | 24.25% |
February 28, 2021 | 24.25% |
January 31, 2021 | 24.25% |
December 31, 2020 | 24.25% |
November 30, 2020 | 24.25% |
October 31, 2020 | 24.25% |
September 30, 2020 | 24.25% |
August 31, 2020 | 24.25% |
July 31, 2020 | 24.25% |
June 30, 2020 | 24.25% |
May 31, 2020 | 24.25% |
April 30, 2020 | 24.25% |
March 31, 2020 | 24.25% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
22.48%
Minimum
Oct 2021
24.25%
Maximum
May 2019
23.32%
Average
22.48%
Median
Oct 2021
Max Drawdown (5Y) Benchmarks
Amgen Inc | 24.86% |
Biogen Inc | 54.78% |
Madrigal Pharmaceuticals Inc | 82.20% |
Vertex Pharmaceuticals Inc | 41.60% |
Viking Therapeutics Inc | 89.26% |